Stay updated on Obinutuzumab in ISN/RPS Class III/IV Lupus Nephritis Clinical Trial
Sign up to get notified when there's something new on the Obinutuzumab in ISN/RPS Class III/IV Lupus Nephritis Clinical Trial page.

Latest updates to the Obinutuzumab in ISN/RPS Class III/IV Lupus Nephritis Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.3.3 has been added to the Record History. The entries 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedThe page history now includes a new revision entry v3.3.2 and removes the previous v3.2.0 revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedRemoved the site-wide government funding operating-status notice from the page, which is not part of the trial data or navigation. The core trial record and its version history remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check57 days agoChange DetectedA new version shows 'Results Posted' for the REGENCY trial (NCT04221477) with Adverse Events and updated Study Status, replacing the previous 'Results Submitted' entry and minor capitalization differences in the title.SummaryDifference0.4%

- Check65 days agoChange DetectedThe record history now lists newer versions, including an IPDSharing entry, while the main study details and status remain unchanged.SummaryDifference0.1%

- Check86 days agoChange DetectedAdded a formal study-reporting structure and status notes (Study Status, Outcome Measures, Participant Flow, etc.) with a conclusion pending date; no deletions observed.SummaryDifference2%

Stay in the know with updates to Obinutuzumab in ISN/RPS Class III/IV Lupus Nephritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Obinutuzumab in ISN/RPS Class III/IV Lupus Nephritis Clinical Trial page.